U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 31 - 40 of 81 results

Status:
Investigational
Source:
INN:ioglucol
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Ioglucol is a triiodoanilide derivative patented by Mallinckrodt, Inc. as nonionic -ray contrast media
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
US Previously Marketed
First approved in 1995

Class (Stereo):
CHEMICAL (MIXED)

Conditions:

Ioxilan is a nonionic X-ray contrast agent approved by the United States Food and Drug Administration for X-ray imaging contrast enhancement. Ioxilan can be administered intravenously for excretory urography and contrast-enhanced computed tomography (CT) imaging of the head and body. Ioxilan can also be given intraarterially for cerebral arteriograpy, coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography.
Status:
US Previously Marketed
First approved in 1989

Class (Stereo):
CHEMICAL (UNKNOWN)


Iotrol, a nonionic dimeric, intrathecal contrast medium for myelography. This agent does not exhibit any cytotoxic effect on human healthy nucleus pulposus (NP) cells.
Ioxaglate Sodium Meglumine (trade name Hexabrix) is a new low osmolality ionic contrast agent, that used as a diagnostic radiopaque medium. Following intravascular injection, Ioxaglate Sodium Meglumine is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine. The joint spaces as well as the uterus and fallopian tubes may be visualized by the direct injection of the contrast medium into the region to be studied. The usual adult dose for left coronary arteriography is 8 mL (range 2-14 mL) and for right coronary arteriography is 5 mL (range 1-10 mL). The doses may be repeated as necessary Patients may have clinically insignificant ECG changes during the procedure. The following adverse effects have occurred in conjunction with the administration of iodinated intravascular contrast agents for this procedure: hypotension, shock, anginal pain, myocardial infarction, cardiac arrhythmias (bradycardia, ventricular tachycardia, ventricular fibrillation) and cardiac arrest.
Status:
US Previously Marketed
First approved in 1981

Class (Stereo):
CHEMICAL (ACHIRAL)


Iodoxamic acid (previously sold under the brand name Cholovue) is an organoiodine compound that was used as a contrast medium. It is intravenous cholecystocholangiographic agent. It features both a high iodine content as well as several hydrophilic groups.
Status:
US Previously Marketed
First approved in 1978

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Iodamide is an ionic monomeric iodinated radiographic contrast medium. It was used in many procedures and may be given intravenously or by other routes, for example by instillation into the bladder or uterus; it has also been used for computed tomography. It is usually given as a 24 to 65% solution of the meglumine salt, or as a mixture of the sodium and meglumine salts; solutions of the sodium salt have also been used. Iodamide is no longer marketed in the US.
Status:
US Previously Marketed
First approved in 1973

Class (Stereo):
CHEMICAL (RACEMIC)


Iocetamic acid is a medical diagnostic aid. It is a contrast agent used to enhance structures or fluids during X-ray imaging.
Status:
US Previously Marketed
Source:
HYTRAST IOPYDONE by FOUGERA
(1962)
Source URL:
First approved in 1962

Class (Stereo):
CHEMICAL (ACHIRAL)

Iopydone is a pyridine derivative patented by Schering-Kahlbaum A.-G. As radiographic contrast medium for bronchography. Hytrast, an aqueous suspension containing Iopydol and Iopydone has widely used in some countries. Extensive clinical trials had suggested that Hytrast was superior to products usually employed for this purpose. Hytrast provides excellent quality bronchograms with a fine dense coating of the bronchial walls and no ‘alveolar filling’.